Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade

Bibliographic Details
Main Authors: David M. Miller, MD, PhD, Beverly E. Faulkner-Jones, MD, PhD, James R. Stone, MD, PhD, Reed E. Drews, MD
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:JAAD Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512617301170
_version_ 1819262623584092160
author David M. Miller, MD, PhD
Beverly E. Faulkner-Jones, MD, PhD
James R. Stone, MD, PhD
Reed E. Drews, MD
author_facet David M. Miller, MD, PhD
Beverly E. Faulkner-Jones, MD, PhD
James R. Stone, MD, PhD
Reed E. Drews, MD
author_sort David M. Miller, MD, PhD
collection DOAJ
first_indexed 2024-12-23T20:00:38Z
format Article
id doaj.art-e92699520dd04da2ad0274f5cdf8b490
institution Directory Open Access Journal
issn 2352-5126
language English
last_indexed 2024-12-23T20:00:38Z
publishDate 2017-09-01
publisher Elsevier
record_format Article
series JAAD Case Reports
spelling doaj.art-e92699520dd04da2ad0274f5cdf8b4902022-12-21T17:33:06ZengElsevierJAAD Case Reports2352-51262017-09-013541241510.1016/j.jdcr.2017.06.005Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockadeDavid M. Miller, MD, PhD0Beverly E. Faulkner-Jones, MD, PhD1James R. Stone, MD, PhD2Reed E. Drews, MD3Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MassachusettsDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, MassachusettsDepartment of Pathology, Massachusetts General Hospital, Boston, MassachusettsDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusettshttp://www.sciencedirect.com/science/article/pii/S2352512617301170immune checkpoint blockadeipilimumabnivolumabsquamous cell carcinoma
spellingShingle David M. Miller, MD, PhD
Beverly E. Faulkner-Jones, MD, PhD
James R. Stone, MD, PhD
Reed E. Drews, MD
Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
JAAD Case Reports
immune checkpoint blockade
ipilimumab
nivolumab
squamous cell carcinoma
title Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
title_full Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
title_fullStr Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
title_full_unstemmed Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
title_short Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
title_sort complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
topic immune checkpoint blockade
ipilimumab
nivolumab
squamous cell carcinoma
url http://www.sciencedirect.com/science/article/pii/S2352512617301170
work_keys_str_mv AT davidmmillermdphd completepathologicresponseofmetastaticcutaneoussquamouscellcarcinomaandallograftrejectionaftertreatmentwithcombinationimmunecheckpointblockade
AT beverlyefaulknerjonesmdphd completepathologicresponseofmetastaticcutaneoussquamouscellcarcinomaandallograftrejectionaftertreatmentwithcombinationimmunecheckpointblockade
AT jamesrstonemdphd completepathologicresponseofmetastaticcutaneoussquamouscellcarcinomaandallograftrejectionaftertreatmentwithcombinationimmunecheckpointblockade
AT reededrewsmd completepathologicresponseofmetastaticcutaneoussquamouscellcarcinomaandallograftrejectionaftertreatmentwithcombinationimmunecheckpointblockade